cilostazol has been researched along with Intermittent Claudication in 128 studies
Intermittent Claudication: A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and safety of cilostazol, pentoxifylline, beraprost for intermittent claudication due to lower extremity arterial occlusive disease." | 9.22 | Systematic review the efficacy and safety of cilostazol, pentoxifylline, beraprost in the treatment of intermittent claudication: A network meta-analysis. ( Cao, Y; Liang, X; Wang, Y; Zhao, C, 2022) |
| "Cilostazol significantly improves ACD, in addition to attenuating exercise-induced ischaemia-reperfusion injury, in PAD patients." | 9.14 | The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. ( Badger, SA; Lee, B; Makar, RR; McEneny, J; O'Donnell, ME; Sharif, MA; Soong, CV; Young, IS, 2009) |
| "Cilostazol improves walking distance in patients with intermittent claudication and reduces restenosis after coronary intervention, but its efficacy remains unclear after EVT for femoropopliteal disease." | 9.14 | Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. ( Hikichi, Y; Kawasaki, T; Nakashima, H; Nobuyoshi, M; Soga, Y; Tsurugida, M; Yokoi, H, 2009) |
| "To determine the effect of cilostazol on initial and absolute claudication distances, mortality and vascular events in patients with stable intermittent claudication." | 9.12 | Cilostazol for intermittent claudication. ( Brown, T; Cleanthis, M; Forster, RB; Mikhailidis, DP; Stansby, G; Stewart, M, 2021) |
| "Remnant lipoprotein concentrations are significantly elevated in patients with intermittent claudication and can be reduced by cilostazol." | 9.10 | Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. ( Elam, MB; Forbes, WP; Nakajima, K; Wang, T; Zhong, J, 2003) |
| "Cilostazol, a novel oral phosphodiesterase inhibitor, has shown consistent improvement in exercise tolerance in patients with intermittent claudication (IC)." | 9.09 | Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. ( Chen, MF; Hwang, JJ; Lee, TM; Lee, YT; Su, SF; Tseng, CD; Wang, SS, 2001) |
| " Cilostazol and pentoxifylline are the only two drugs that have been approved for the treatment of patients with intermittent claudication." | 9.09 | Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. ( Lee, TM; Lee, YT; Su, SF; Tsai, CH; Wang, SS, 2001) |
| "Cilostazol was significantly better than pentoxifylline or placebo for increasing walking distances in patients with intermittent claudication, but was associated with a greater frequency of minor side effects." | 9.09 | A comparison of cilostazol and pentoxifylline for treating intermittent claudication. ( Bortey, EB; Cutler, BS; Dawson, DL; Forbes, WP; Hiatt, WR; Hobson, RW; Martin, JD; Strandness, DE, 2000) |
| "This study evaluated the effects of cilostazol on walking distances in patients with intermittent claudication (IC) caused by peripheral arterial occlusive disease." | 9.08 | Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. ( Cutler, B; Davidson, M; Forbes, WP; Heckman, J; Herd, JA; Isaacsohn, JL; Money, SR, 1998) |
| "To determine the effect of cilostazol (an antiplatelet treatment) on improving initial and absolute claudication distances, and in reducing mortality and vascular events in patients with stable intermittent claudication." | 8.90 | Cilostazol for intermittent claudication. ( Bedenis, R; Cleanthis, M; Mikhailidis, DP; Robless, P; Stansby, G; Stewart, M, 2014) |
| "A systematic review and network meta-analysis was undertaken to consider the evidence for the efficacy and tolerability of placebo, cilostazol, naftidrofuryl oxalate and pentoxifylline in patients with intermittent claudication due to peripheral arterial disease (PAD)." | 8.88 | Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. ( Harnan, S; Meng, Y; Michaels, J; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2012) |
| "This paper represents a review, by experts, of current opinion and information on intermittent claudication (IC) and the role that cilostazol plays in its treatment." | 8.82 | The role of cilostazol in the treatment of intermittent claudication. ( Barnett, AH; Bradbury, AW; Brittenden, J; Crichton, B; Donnelly, R; Homer-Vanniasinkam, S; Mikhailidis, DP; Stansby, G, 2004) |
| "To study the effectiveness for the treatment of intermittent claudication (IC) of three drugs with antiplatelet effects, cilostazol, beraprost sodium, and prostaglandin E(1) (PGE(1)), by using a systemic review of literature and a meta-analysis." | 8.82 | Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication. ( Hashiguchi, M; Ohno, K; Saito, R, 2004) |
| "In six of eight well designed clinical trials, cilostazol was significantly more effective than placebo in increasing walking distances and improving the quality of life of patients with moderate to severe intermittent claudication." | 8.82 | Cilostazol: a review of its use in intermittent claudication. ( Chapman, TM; Goa, KL, 2003) |
| "To assess whether cilostazol, a phosphodiesterase III inhibitor, improves treadmill and community-based walking ability and health-related quality of life (HQL) in patients with intermittent claudication resulting from peripheral arterial disease (PAD)." | 8.81 | Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. ( Forbes, WP; Heckman, J; Hiatt, WR; McCarthy, WJ; Regensteiner, JG; Ware, JE; Zhang, P, 2002) |
| "The pathophysiology of intermittent claudication (IC) and the role of pentoxifylline and cilostazol for treating IC are discussed." | 8.81 | Treatment of intermittent claudication with pentoxifylline and cilostazol. ( Riemann, LE; Tjon, JA, 2001) |
| "To review the pharmacology and clinical utility of cilostazol, an antiplatelet and vasodilator agent approved for the management of intermittent claudication." | 8.81 | Cilostazol: treatment of intermittent claudication. ( Mohler, ER; Reilly, MP, 2001) |
| "to assess the effects of cilostazol on pain-free walking distance in PAD patients with IC at 3 and 6 months in a real world, prospective, observational study." | 8.12 | Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease. ( Giannoukas, A; Katsiki, N; Koufaki, P; Marakomichelakis, G; Papanas, N; Richter, D; Tentolouris, N, 2022) |
| "Cilostazol (CLZ) is an FDA approved therapeutic that is indicated for patients with intermittent claudication disease." | 7.81 | Cilostazol blocks pregnancy in naturally cycling swine: An animal model. ( Ash, O; Fajt, V; Kraemer, DC; Muhsen-Alanssari, SA; Ridha-Albarzanchi, MT; Taiyeb, AM, 2015) |
| "We assessed the cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for intermittent claudication due to peripheral arterial disease (PAD) in adults whose symptoms continue despite a period of conventional management." | 7.80 | Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. ( Harnan, S; Meng, Y; Michaels, J; O'Donnell, ME; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2014) |
| "To estimate the cost effectiveness of cilostazol (Pletal) compared to naftidrofuryl and pentoxifylline (Trental) in the treatment of intermittent claudication in the UK." | 7.73 | Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK. ( Clegg, JP; Davie, AM; Guest, JF, 2005) |
| "The systemic treatment effects of OP-1206 alpha-CD (17S-20-dimethyl-trans-delta 2-PGE1 alpha-cyclodextrin clathrate), a prostaglandin E1 (PGE1) analogue, on walking dysfunction, spinal cord blood flow (SCBF) and skin blood flow (SKBF) were assessed in the rat neuropathic intermittent claudication (IC) model in comparison with nifedipine (dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate), ticlopidine (5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-C]pyridine hydrochloride) and cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone)." | 7.72 | Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol. ( Akimaru, S; Ito, H; Katsube, N; Maegawa, H; Marsala, M; Nakai, K; Takenobu, Y; Takimizu, H, 2003) |
| "Cilostazol (Pletal), a quinolinone derivative with a cyclic nucleotide phosphodiesterase type 3 (PDE3) inhibitory activity, was recently approved by the Food and Drug Administration for treatment of symptoms of intermittent claudication (IC)." | 7.70 | Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. ( Cone, J; Fong, M; Kambayashi, J; Liu, Y; Wang, S; Yoshitake, M, 2000) |
| " Adverse events were monitored throughout the study." | 6.71 | Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication. ( Bajaj, P; Ballary, C; Desai, A; Devani, RG; Potdar, NP; Samra, SS; Vijayaraghavan, KS; Vyas, D, 2003) |
| "Cilostazol was well tolerated in healthy volunteers and patients with intermittent claudication resulting from PAD." | 6.69 | Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. ( Bramer, SL; Forbes, WP; Mallikaarjun, S, 1999) |
| "Cilostazol treatment resulted in a 35% increase in treadmill walking time (P=0." | 6.69 | Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. ( Bortey, EB; Crouse, JR; Davidson, M; Elam, MB; Forbes, WP; Gordon, IL; Heckman, J; Herd, JA; Hunninghake, DB, 1998) |
| "Cilostazol is a new phosphodiesterase inhibitor that suppresses platelet aggregation and also acts as a direct arterial vasodilator." | 6.69 | Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. ( Cutler, BS; Dawson, DL; Meissner, MH; Strandness, DE, 1998) |
| "Cilostazol did not increase the risk of all-cause mortality (RR 0." | 6.46 | A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. ( Creager, MA; Hiatt, WR; Hittel, N; Pande, RL; Zhang, P, 2010) |
| "Intermittent claudication is a potentially disabling disorder that impairs quality of life and is a marker of underlying cardiovascular disease." | 6.42 | Treatment of intermittent claudication: cilostazol. ( Brittenden, J; Collins, P, 2004) |
| "Intermittent claudication is a common, disabling symptom of peripheral arterial disease that limits walking distance and is associated with an increased cardiovascular risk of acute limb- or life-threatening complications." | 6.42 | Cilostazol: improving walking distance in patients with intermittent claudication. ( Collinson, DJ; Donnelly, R, 2004) |
| "Cilostazol-treated patients reported a higher incidence of headache, bowel complaints, and palpitations than patients given placebos." | 6.41 | Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. ( Forbes, WP; Thompson, PD; Zhang, P; Zimet, R, 2002) |
| "Cilostazol is a phosphodiesterase III inhibitor with antiplatelet, antithrombotic and vasodilatory effects." | 6.41 | Cilostazol: a novel treatment option in intermittent claudication. ( Cariski, AT, 2001) |
| "Cilostazol treatment showed statistically significant increases in MWD and PFWD within 4 weeks, as well as improvements in physical functional status at 24 weeks, compared with placebo and pentoxifylline." | 6.41 | Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication. ( Smith, JA, 2002) |
| "Cilostazol is a new drug for the treatment of claudication." | 6.41 | Comparative effects of cilostazol and other therapies for intermittent claudication. ( Dawson, DL, 2001) |
| "Cilostazol was registered in Hungary in 2014." | 5.46 | [Cilostazol is effective and safe option for the treatment of intermittent claudication. Results of the NOCLAUD study]. ( Farkas, K; Járai, Z; Kolossváry, E, 2017) |
| "This study was aimed at assessing tolerability, safety and therapeutic efficacy of Pletax® (cilostazol) compared with Trental® (pentoxifylline) in patients with moderate-to-severe intermittent claudication." | 5.41 | [Randomized study of tolerability, safety and efficacy of Pletax in intermittent claudication]. ( Erofeeva, SB; Ershova, OB; Goriunov, SV; Gurgenian, EV; Kazantsev, AN, 2021) |
| "Intermittent claudication affects 5% of the middle-aged population in developed countries and is associated with a significant reduction in health-related quality of life and cardiovascular morbidity and mortality." | 5.32 | The role of cilostazol (Pletal) in the management of intermittent claudication. ( Bradbury, AW, 2003) |
| "Primarily used in the treatment of intermittent claudication, cilostazol is a 2-oxyquinolone derivative that works through the inhibition of phosphodiesterase III and related increases in cyclic adenosine monophosphate (cAMP) levels." | 5.22 | Cilostazol: a Review of Basic Mechanisms and Clinical Uses. ( Angiolillo, D; Birnbaum, Y; Khawaja, M; Kherallah, RY; Olson, M, 2022) |
| "Cilostazol, a phosphodiesterase III inhibitor, has vasodilating and antiplatelet properties with a low rate of bleeding complications." | 5.22 | Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications. ( Manolis, AA; Manolis, AS; Manolis, TA; Melita, H; Mikhailidis, DP, 2022) |
| "Cilostazol significantly improves ACD, in addition to attenuating exercise-induced ischaemia-reperfusion injury, in PAD patients." | 5.14 | The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. ( Badger, SA; Lee, B; Makar, RR; McEneny, J; O'Donnell, ME; Sharif, MA; Soong, CV; Young, IS, 2009) |
| "Cilostazol improves walking distance in patients with intermittent claudication and reduces restenosis after coronary intervention, but its efficacy remains unclear after EVT for femoropopliteal disease." | 5.14 | Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. ( Hikichi, Y; Kawasaki, T; Nakashima, H; Nobuyoshi, M; Soga, Y; Tsurugida, M; Yokoi, H, 2009) |
| "Cilostazol, a phosphodiesterase III inhibitor, is indicated to treat the symptoms of intermittent claudication and increase walking distance in patients with peripheral arterial disease (PAD)." | 5.13 | Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). ( Brass, EP; Hiatt, WR; Money, SR, 2008) |
| "Background No network meta-analysis has considered the relative efficacy of cilostazol, home exercise therapy, supervised exercise therapy (SET), endovascular revascularization (ER), and ER plus SET (ER+SET) in improving maximum walking distance (MWD) over short- (<1 year), moderate- (1 to <2 years), and long-term (≥2 years) follow-up in people with intermittent claudication." | 5.12 | Network Meta-Analysis Comparing the Outcomes of Treatments for Intermittent Claudication Tested in Randomized Controlled Trials. ( Golledge, J; Huynh, P; Ibrahim, M; Jones, R; Moxon, J; Phie, J; Sharma, C; Thanigaimani, S; Wong, S, 2021) |
| "To determine the effect of cilostazol on initial and absolute claudication distances, mortality and vascular events in patients with stable intermittent claudication." | 5.12 | Cilostazol for intermittent claudication. ( Brown, T; Cleanthis, M; Forster, RB; Mikhailidis, DP; Stansby, G; Stewart, M, 2021) |
| "Diabetic and non-diabetic patients with intermittent claudication respond favourably to cilostazol, with no significant difference in their overall response." | 5.10 | Cilostazol treatment of claudication in diabetic patients. ( Cariski, AT; Hittel, N; Rendell, M; Zhang, P, 2002) |
| "Remnant lipoprotein concentrations are significantly elevated in patients with intermittent claudication and can be reduced by cilostazol." | 5.10 | Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. ( Elam, MB; Forbes, WP; Nakajima, K; Wang, T; Zhong, J, 2003) |
| " Cilostazol and pentoxifylline are the only two drugs that have been approved for the treatment of patients with intermittent claudication." | 5.09 | Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. ( Lee, TM; Lee, YT; Su, SF; Tsai, CH; Wang, SS, 2001) |
| "To evaluate the safety and efficacy of cilostazol for the treatment of intermittent claudication." | 5.09 | A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. ( Beebe, HG; Bortey, EB; Cutler, BS; Dawson, DL; Forbes, WP; Herd, JA; Strandness, DE, 1999) |
| "This study evaluated the effects of cilostazol on walking distances in patients with intermittent claudication (IC) caused by peripheral arterial occlusive disease." | 5.08 | Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. ( Cutler, B; Davidson, M; Forbes, WP; Heckman, J; Herd, JA; Isaacsohn, JL; Money, SR, 1998) |
| "To determine the effect of cilostazol (an antiplatelet treatment) on improving initial and absolute claudication distances, and in reducing mortality and vascular events in patients with stable intermittent claudication." | 4.90 | Cilostazol for intermittent claudication. ( Bedenis, R; Cleanthis, M; Mikhailidis, DP; Robless, P; Stansby, G; Stewart, M, 2014) |
| "A systematic review and network meta-analysis was undertaken to consider the evidence for the efficacy and tolerability of placebo, cilostazol, naftidrofuryl oxalate and pentoxifylline in patients with intermittent claudication due to peripheral arterial disease (PAD)." | 4.88 | Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. ( Harnan, S; Meng, Y; Michaels, J; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2012) |
| " Randomised placebo controlled trials have shown that the phosphodiesterase III inhibitor cilostazol 100mg bid improves pain-free and maximum walking distance, as well as quality of life, in a range of patients with intermittent claudication in whom there is no evidence of tissue necrosis or rest pain." | 4.84 | Medical therapy for intermittent claudication. ( Donnelly, R; Rowlands, TE, 2007) |
| "To study the effectiveness for the treatment of intermittent claudication (IC) of three drugs with antiplatelet effects, cilostazol, beraprost sodium, and prostaglandin E(1) (PGE(1)), by using a systemic review of literature and a meta-analysis." | 4.82 | Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication. ( Hashiguchi, M; Ohno, K; Saito, R, 2004) |
| "The US FDA has approved two drugs for the management of intermittent claudication: pentoxifylline and cilostazol." | 4.82 | Drug treatment of intermittent claudication. ( Jacoby, D; Mohler, ER, 2004) |
| " Among the key recommendations in this chapter are the following: For patients with chronic limb ischemia, we recommend lifelong aspirin therapy in comparison to no antiplatelet therapy in patients with clinically manifest coronary or cerebrovascular disease (Grade 1A) and in those without clinically manifest coronary or cerebrovascular disease (Grade 1C+)." | 4.82 | Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. ( Clagett, GP; Jackson, MR; Lip, GY; Sobel, M; Tangelder, M; Verhaeghe, R, 2004) |
| "This paper represents a review, by experts, of current opinion and information on intermittent claudication (IC) and the role that cilostazol plays in its treatment." | 4.82 | The role of cilostazol in the treatment of intermittent claudication. ( Barnett, AH; Bradbury, AW; Brittenden, J; Crichton, B; Donnelly, R; Homer-Vanniasinkam, S; Mikhailidis, DP; Stansby, G, 2004) |
| "To assess whether cilostazol, a phosphodiesterase III inhibitor, improves treadmill and community-based walking ability and health-related quality of life (HQL) in patients with intermittent claudication resulting from peripheral arterial disease (PAD)." | 4.81 | Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. ( Forbes, WP; Heckman, J; Hiatt, WR; McCarthy, WJ; Regensteiner, JG; Ware, JE; Zhang, P, 2002) |
| "Cilostazol is an antiplatelet agent with vasodilating properties that has been used in the treatment of patients with peripheral ischaemia such as intermittent claudication." | 4.80 | Cilostazol. ( Markham, A; Sorkin, EM, 1999) |
| "Cilostazol is the only first-line medication for treating intermittent claudication, and the controlled-release (CR) formulation is associated with a lower prevalence of adverse events (AEs)." | 4.31 | Real-World Safety and Effectiveness of Controlled-Release Cilostazol in Patients with Symptomatic Peripheral Artery Disease. ( Kim, JH; Lee, HJ; Shin, WY, 2023) |
| "to assess the effects of cilostazol on pain-free walking distance in PAD patients with IC at 3 and 6 months in a real world, prospective, observational study." | 4.12 | Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease. ( Giannoukas, A; Katsiki, N; Koufaki, P; Marakomichelakis, G; Papanas, N; Richter, D; Tentolouris, N, 2022) |
| "The aim of this study was to evaluate the effect of a three-month cilostazol treatment on the health-related quality of life and on the lower-limb functional capacity in diabetic (DM) and non-diabetic patients (NDM) with intermittent claudication in the clinical practice." | 3.96 | Cilostazol improves the quality of life and lower-limb functional capacity also in diabetic patients ( Farkas, K; Járai, Z; Kolossváry, E, 2020) |
| "The study was aimed at assessing efficacy and safety of treatment with Aducil® (cilostazol) compared with Trental® 400 in patients with moderate-to-severe intermittent claudication due to peripheral atherosclerosis." | 3.91 | [Clinical study of efficacy and safety of Aducil in patients with chronic lower limb ischaemia]. ( Chupin, AV; Gadzhimuradov, RU; Kalinin, RE; Kamaev, AA; Lar'kov, RN; Parshin, PI; Porsheneva, EV; Suchkov, IA; Uchkin, IG, 2019) |
| "The purpose of the study is to evaluate the effectiveness of risk minimization measures-labeling changes and communication to health care professionals-recommended by the European Medicines Agency for use of cilostazol for the treatment of intermittent claudication in Europe." | 3.88 | Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany. ( Arana, A; Bui, C; Calingaert, B; Castellsague, J; Giner-Soriano, M; Gonzalez-Rubio, F; Laguna, C; Linder, M; Perez-Gutthann, S; Poblador-Plou, B; Prados-Torres, A; Roso-Llorach, A; Scholle, O, 2018) |
| "Cilostazol (CLZ) is an FDA approved therapeutic that is indicated for patients with intermittent claudication disease." | 3.81 | Cilostazol blocks pregnancy in naturally cycling swine: An animal model. ( Ash, O; Fajt, V; Kraemer, DC; Muhsen-Alanssari, SA; Ridha-Albarzanchi, MT; Taiyeb, AM, 2015) |
| "We assessed the cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for intermittent claudication due to peripheral arterial disease (PAD) in adults whose symptoms continue despite a period of conventional management." | 3.80 | Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. ( Harnan, S; Meng, Y; Michaels, J; O'Donnell, ME; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2014) |
| "Cilostazol increases the walking distance in patients with intermittent claudication, but there is scarce evidence of any effect on the risk for subsequent ischemic events, bleeding or death." | 3.80 | Cilostazol and outcome in outpatients with peripheral artery disease. ( Aguilar, E; Esteban, C; Jiménez Caballero, PE; Manzano, L; Monreal, M; Mujal, A; Perez, P; Sánchez Muñoz-Torrero, JF; Sauquillo, JC; Yeste, M, 2014) |
| " Cilostazol is a drug approved by the US Food and Drug Administration for the treatment of intermittent claudication." | 3.79 | Cilostazol promotes mitochondrial biogenesis in human umbilical vein endothelial cells through activating the expression of PGC-1α. ( Ge, Z; Li, Q; Sun, B; Xu, Z; Zuo, L, 2013) |
| " For this study, 20 PAD patients were assigned to take either pentoxifylline (n=11) or cilostazol (n=9), the two FDA-approved pharmacological therapies used to treat intermittent claudication symptoms." | 3.76 | Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes. ( Huisinga, JM; Johanning, JM; Pipinos, II; Stergiou, N, 2010) |
| "To estimate the cost effectiveness of cilostazol (Pletal) compared to naftidrofuryl and pentoxifylline (Trental) in the treatment of intermittent claudication in the UK." | 3.73 | Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK. ( Clegg, JP; Davie, AM; Guest, JF, 2005) |
| "The systemic treatment effects of OP-1206 alpha-CD (17S-20-dimethyl-trans-delta 2-PGE1 alpha-cyclodextrin clathrate), a prostaglandin E1 (PGE1) analogue, on walking dysfunction, spinal cord blood flow (SCBF) and skin blood flow (SKBF) were assessed in the rat neuropathic intermittent claudication (IC) model in comparison with nifedipine (dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate), ticlopidine (5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-C]pyridine hydrochloride) and cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone)." | 3.72 | Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol. ( Akimaru, S; Ito, H; Katsube, N; Maegawa, H; Marsala, M; Nakai, K; Takenobu, Y; Takimizu, H, 2003) |
| "Cilostazol, a type III phosphodiesterase inhibitor, was approved in the United States in 1999 for the reduction of the symptoms of intermittent claudication." | 3.71 | Analysis of the cilostazol safety database. ( Pratt, CM, 2001) |
| "Cilostazol (Pletal), a quinolinone derivative with a cyclic nucleotide phosphodiesterase type 3 (PDE3) inhibitory activity, was recently approved by the Food and Drug Administration for treatment of symptoms of intermittent claudication (IC)." | 3.70 | Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. ( Cone, J; Fong, M; Kambayashi, J; Liu, Y; Wang, S; Yoshitake, M, 2000) |
| "Cilostazol is an antiplatelet, antithrombotic agent, which has been used for the treatment of PAOD." | 2.80 | Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products. ( Chen, JH; Chuang, TJ; Hsiao, FC; Hsieh, CH; Hung, YJ; Lee, CH; Lin, TK; Liu, JS, 2015) |
| "Aspirin and placebo treatment were associated with elevated P-selectin expression, platelet-monocyte aggregation and reduced CD42b expression (p<0." | 2.74 | Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation. ( Ashour, H; Bhattacharya, V; Cleanthis, M; Smout, J; Stansby, G, 2009) |
| "Cilostazol is a selective inhibitor of phosphodiesterase III with anti-platelet-aggregatory and vasodilating properties." | 2.71 | Effects of cilostazol on lipid and fatty acid metabolism. ( Hamazaki, T; Nakamura, N; Okumura, K; Osawa, H; Yamabe, H, 2005) |
| "Cilostazol is a new phosphodiesterase inhibitor that suppresses platelet aggregation and also acts as a direct arterial vasodilator." | 2.69 | Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. ( Cutler, BS; Dawson, DL; Meissner, MH; Strandness, DE, 1998) |
| "Pharmacologic treatment for intermittent claudication is a management option." | 2.69 | The effect of withdrawal of drugs treating intermittent claudication. ( Bradley, DV; Britt, KE; Charles, BE; Dawson, DL; DeMaioribus, CA; Hagino, RT; Light, JT, 1999) |
| "Cilostazol was well tolerated in healthy volunteers and patients with intermittent claudication resulting from PAD." | 2.69 | Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. ( Bramer, SL; Forbes, WP; Mallikaarjun, S, 1999) |
| " Rivaroxaban of low dosage (2." | 2.61 | How To Assess a Claudication and When To Intervene. ( Armstrong, EJ; Hossain, P; Kokkinidis, DG, 2019) |
| "Cilostazol is a unique antiplatelet agent that has been commercially available for over two decades." | 2.52 | Clinical efficacy and safety of cilostazol: a critical review of the literature. ( Finks, SW; Oliphant, CS; Rogers, KC, 2015) |
| "In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb." | 2.50 | Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014) |
| "Food and Drug Administration for the treatment of intermittent claudication, several supplements and investigational agents have been evaluated." | 2.45 | Pharmacologic therapy for intermittent claudication. ( Dobesh, PP; Persson, EL; Stacy, ZA, 2009) |
| "The key areas of treatment focus on smoking cessation, exercise rehabilitation, with supervised therapy if possible, cardiovascular risk prevention with antiplatelet drugs, statins and angiotensin converting enzymes, and correction of atherosclerotic risk factors with well-defined targets (LDL less than 1g/L, HDL greater than 0." | 2.45 | [Peripheral arterial disease with lower limb claudication: Medical treatment]. ( Bui, HT; Hadj Henni, A; Journet, J; Long, A, 2009) |
| "Cilostazol has been shown to be of benefit in improving walking distance in people with IC." | 2.44 | Cilostazol for peripheral arterial disease. ( Mikhailidis, DP; Robless, P; Stansby, GP, 2007) |
| "Cilostazol has been shown to be of benefit in improving walking distance in people with IC." | 2.44 | Cilostazol for peripheral arterial disease. ( Mikhailidis, DP; Robless, P; Stansby, GP, 2008) |
| "Intermittent claudication is a potentially disabling disorder that impairs quality of life and is a marker of underlying cardiovascular disease." | 2.42 | Treatment of intermittent claudication: cilostazol. ( Brittenden, J; Collins, P, 2004) |
| "Intermittent claudication is a common disabling condition that affects approximately 5% to 15% of patients with atherosclerotic disease." | 2.41 | Can claudication be improved with medication? ( Conners, MS; Money, SR, 2002) |
| "Cilostazol-treated patients reported a higher incidence of headache, bowel complaints, and palpitations than patients given placebos." | 2.41 | Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. ( Forbes, WP; Thompson, PD; Zhang, P; Zimet, R, 2002) |
| "Cilostazol is a phosphodiesterase III inhibitor with antiplatelet, antithrombotic and vasodilatory effects." | 2.41 | Cilostazol: a novel treatment option in intermittent claudication. ( Cariski, AT, 2001) |
| "Cilostazol has also been shown to improve the physical dimensions of quality of life." | 2.41 | New treatment options in intermittent claudication: the US experience. ( Hiatt, WR, 2001) |
| "Cilostazol has also been shown to be significantly more effective than pentoxifylline in improving pain-free and maximal walking distance." | 2.41 | Intermittent claudication: effective medical management of a common circulatory problem. ( Beebe, HG, 2001) |
| "Cilostazol is a new drug for the treatment of claudication." | 2.41 | Comparative effects of cilostazol and other therapies for intermittent claudication. ( Dawson, DL, 2001) |
| "Cilostazol treatment showed statistically significant increases in MWD and PFWD within 4 weeks, as well as improvements in physical functional status at 24 weeks, compared with placebo and pentoxifylline." | 2.41 | Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication. ( Smith, JA, 2002) |
| "Intermittent claudication is a form of exercise intolerance characterized by muscle pain during walking in patients with peripheral artery disease (PAD)." | 1.40 | Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice. ( Alcantara, R; Baltgalvis, KA; Claypool, MD; Friera, AM; Godinez, G; Goff, D; Gururaja, T; Hansen, D; Hitoshi, Y; Jenkins, Y; Kinsella, TM; Lang, W; Lau, D; Li, W; Li, Y; Markovtsov, V; McCaughey, K; McLaughlin, J; Nguyen, H; Pan, A; Park, G; Payan, DG; Shaw, SJ; Singh, BK; Singh, R; Smith, IJ; Sun, TQ; Uy, G; White, K, 2014) |
| "For cilostazol, 300 mg/kg was effective." | 1.34 | NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model. ( Asakura, Y; Hori, M; Ishiwata, N; Ito, Y; Kawanishi, M; Mitani, A; Nakaike, S; Nishiyama, H; Noguchi, K; Shudo, N; Takahashi, K; Takahashi, S; Tsuruzoe, N, 2007) |
| "Cilostazol was discontinued, and shortly thereafter the ventricular tachycardia subsided." | 1.31 | Rapid ventricular tachycardias associated with cilostazol use. ( Gamssari, F; Garcia, E; Ho, JS; Liu, B; Mahmood, H; Massumi, A; Rasekh, A; Villareal, RP, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (8.59) | 18.2507 |
| 2000's | 71 (55.47) | 29.6817 |
| 2010's | 33 (25.78) | 24.3611 |
| 2020's | 13 (10.16) | 2.80 |
| Authors | Studies |
|---|---|
| Manolis, AA | 1 |
| Manolis, TA | 1 |
| Melita, H | 1 |
| Mikhailidis, DP | 6 |
| Manolis, AS | 1 |
| Lauters, R | 1 |
| Wilkin, D | 1 |
| Liang, X | 1 |
| Wang, Y | 1 |
| Zhao, C | 1 |
| Cao, Y | 1 |
| Katsiki, N | 1 |
| Tentolouris, N | 1 |
| Marakomichelakis, G | 1 |
| Richter, D | 1 |
| Giannoukas, A | 1 |
| Koufaki, P | 1 |
| Papanas, N | 1 |
| Shin, WY | 1 |
| Lee, HJ | 1 |
| Kim, JH | 1 |
| Suchkov, IA | 1 |
| Kalinin, RE | 1 |
| Gadzhimuradov, RU | 1 |
| Lar'kov, RN | 1 |
| Uchkin, IG | 1 |
| Chupin, AV | 1 |
| Parshin, PI | 1 |
| Kamaev, AA | 1 |
| Porsheneva, EV | 1 |
| Hossain, P | 1 |
| Kokkinidis, DG | 1 |
| Armstrong, EJ | 1 |
| Bartholomew, J | 1 |
| Bishop, GJ | 1 |
| Mohammed, M | 1 |
| Gosch, K | 1 |
| Safley, D | 1 |
| Jelani, QU | 1 |
| Aronow, HD | 1 |
| Mena, C | 1 |
| Shishehbor, MH | 1 |
| Spertus, JA | 1 |
| Abbott, JD | 1 |
| Smolderen, KG | 1 |
| Farkas, K | 2 |
| Kolossváry, E | 2 |
| Járai, Z | 2 |
| Burleva, EP | 1 |
| Korelin, SV | 1 |
| Kazantsev, AN | 1 |
| Goriunov, SV | 1 |
| Ershova, OB | 1 |
| Erofeeva, SB | 1 |
| Gurgenian, EV | 1 |
| Kherallah, RY | 1 |
| Khawaja, M | 1 |
| Olson, M | 1 |
| Angiolillo, D | 1 |
| Birnbaum, Y | 1 |
| Thanigaimani, S | 1 |
| Phie, J | 1 |
| Sharma, C | 1 |
| Wong, S | 1 |
| Ibrahim, M | 1 |
| Huynh, P | 1 |
| Moxon, J | 1 |
| Jones, R | 1 |
| Golledge, J | 1 |
| Brown, T | 1 |
| Forster, RB | 1 |
| Cleanthis, M | 3 |
| Stansby, G | 7 |
| Stewart, M | 2 |
| Fakhry, F | 1 |
| Fokkenrood, HJ | 1 |
| Spronk, S | 1 |
| Teijink, JA | 1 |
| Rouwet, EV | 1 |
| Hunink, MGM | 1 |
| Soga, Y | 2 |
| Hamasaki, T | 1 |
| Edahiro, R | 1 |
| Iida, O | 1 |
| Inoue, N | 1 |
| Suzuki, K | 1 |
| Yokoi, Y | 1 |
| Kawasaki, D | 1 |
| Zen, K | 1 |
| Urasawa, K | 1 |
| Aodo, K | 1 |
| Castellsague, J | 1 |
| Poblador-Plou, B | 1 |
| Giner-Soriano, M | 1 |
| Linder, M | 1 |
| Scholle, O | 1 |
| Calingaert, B | 1 |
| Bui, C | 1 |
| Arana, A | 1 |
| Laguna, C | 1 |
| Gonzalez-Rubio, F | 1 |
| Roso-Llorach, A | 1 |
| Prados-Torres, A | 1 |
| Perez-Gutthann, S | 1 |
| Zuo, L | 1 |
| Li, Q | 1 |
| Sun, B | 1 |
| Xu, Z | 1 |
| Ge, Z | 1 |
| de Franciscis, S | 1 |
| Gallelli, L | 1 |
| Battaglia, L | 1 |
| Molinari, V | 1 |
| Montemurro, R | 1 |
| Stillitano, DM | 1 |
| Buffone, G | 1 |
| Serra, R | 1 |
| Melzer, J | 1 |
| Saller, R | 1 |
| Lee, C | 1 |
| Nelson, PR | 1 |
| Baltgalvis, KA | 1 |
| White, K | 1 |
| Li, W | 1 |
| Claypool, MD | 1 |
| Lang, W | 1 |
| Alcantara, R | 1 |
| Singh, BK | 1 |
| Friera, AM | 1 |
| McLaughlin, J | 1 |
| Hansen, D | 1 |
| McCaughey, K | 1 |
| Nguyen, H | 1 |
| Smith, IJ | 1 |
| Godinez, G | 1 |
| Shaw, SJ | 1 |
| Goff, D | 1 |
| Singh, R | 1 |
| Markovtsov, V | 1 |
| Sun, TQ | 1 |
| Jenkins, Y | 1 |
| Uy, G | 1 |
| Li, Y | 1 |
| Pan, A | 1 |
| Gururaja, T | 1 |
| Lau, D | 1 |
| Park, G | 1 |
| Hitoshi, Y | 1 |
| Payan, DG | 1 |
| Kinsella, TM | 1 |
| Perez, P | 1 |
| Esteban, C | 1 |
| Sauquillo, JC | 1 |
| Yeste, M | 1 |
| Manzano, L | 1 |
| Mujal, A | 1 |
| Jiménez Caballero, PE | 1 |
| Aguilar, E | 1 |
| Sánchez Muñoz-Torrero, JF | 1 |
| Monreal, M | 1 |
| Hong, H | 1 |
| Mackey, WC | 1 |
| Di Minno, G | 1 |
| Spadarella, G | 1 |
| Cafaro, G | 1 |
| Petitto, M | 1 |
| Lupoli, R | 1 |
| Di Minno, A | 1 |
| de Gaetano, G | 1 |
| Tremoli, E | 1 |
| Bedenis, R | 1 |
| Robless, P | 3 |
| Agrawal, K | 1 |
| Eberhardt, RT | 1 |
| Liu, JS | 1 |
| Chuang, TJ | 1 |
| Chen, JH | 1 |
| Lee, CH | 1 |
| Hsieh, CH | 1 |
| Lin, TK | 1 |
| Hsiao, FC | 1 |
| Hung, YJ | 1 |
| Rogers, KC | 1 |
| Oliphant, CS | 1 |
| Finks, SW | 1 |
| Guo, J | 1 |
| Chen, W | 1 |
| Wang, G | 1 |
| Zhu, F | 1 |
| Vemulapalli, S | 1 |
| Dolor, RJ | 1 |
| Hasselblad, V | 1 |
| Subherwal, S | 1 |
| Schmit, KM | 1 |
| Heidenfelder, BL | 1 |
| Patel, MR | 1 |
| Schuyler Jones, W | 1 |
| Taiyeb, AM | 1 |
| Muhsen-Alanssari, SA | 1 |
| Kraemer, DC | 1 |
| Ash, O | 1 |
| Fajt, V | 1 |
| Ridha-Albarzanchi, MT | 1 |
| Cimminiello, C | 1 |
| Polo Friz, H | 1 |
| Marano, G | 1 |
| Arpaia, G | 1 |
| Boracchi, P | 1 |
| Spezzigu, G | 1 |
| Visonà, A | 1 |
| McDermott, MM | 1 |
| Kibbe, MR | 1 |
| O'Donnell, ME | 2 |
| Badger, SA | 1 |
| Sharif, MA | 1 |
| Makar, RR | 1 |
| McEneny, J | 1 |
| Young, IS | 1 |
| Lee, B | 1 |
| Soong, CV | 1 |
| Yokoi, H | 1 |
| Kawasaki, T | 1 |
| Nakashima, H | 1 |
| Tsurugida, M | 1 |
| Hikichi, Y | 1 |
| Nobuyoshi, M | 1 |
| Bhattacharya, V | 2 |
| Smout, J | 1 |
| Ashour, H | 1 |
| Chi, YW | 1 |
| Lavie, CJ | 1 |
| Milani, RV | 1 |
| White, CJ | 1 |
| Dobesh, PP | 1 |
| Stacy, ZA | 1 |
| Persson, EL | 1 |
| Long, A | 1 |
| Bui, HT | 1 |
| Journet, J | 1 |
| Hadj Henni, A | 1 |
| Pande, RL | 1 |
| Hiatt, WR | 11 |
| Zhang, P | 5 |
| Hittel, N | 2 |
| Creager, MA | 1 |
| Olin, JW | 2 |
| Sealove, BA | 1 |
| Huisinga, JM | 2 |
| Pipinos, II | 2 |
| Stergiou, N | 2 |
| Johanning, JM | 2 |
| Brass, EP | 2 |
| Cooper, LT | 1 |
| Morgan, RE | 1 |
| Squires, H | 3 |
| Simpson, E | 3 |
| Meng, Y | 3 |
| Harnan, S | 3 |
| Stevens, J | 1 |
| Wong, R | 1 |
| Thomas, S | 3 |
| Michaels, J | 3 |
| Goldenberg, NA | 1 |
| Krantz, MJ | 1 |
| Yentes, JM | 1 |
| Myers, SA | 1 |
| Bertelli, L | 1 |
| Amato, A | 1 |
| Sangiorgi, GM | 1 |
| Stevens, JW | 2 |
| Donnelly, R | 4 |
| Grouse, JR | 1 |
| Allan, MC | 1 |
| Elam, MB | 3 |
| Regensteiner, JG | 3 |
| Ware, JE | 1 |
| McCarthy, WJ | 1 |
| Forbes, WP | 9 |
| Heckman, J | 4 |
| Conners, MS | 1 |
| Money, SR | 3 |
| Thompson, PD | 1 |
| Zimet, R | 2 |
| Rendell, M | 1 |
| Cariski, AT | 3 |
| Bradbury, AW | 3 |
| Nakai, K | 1 |
| Takenobu, Y | 1 |
| Takimizu, H | 1 |
| Akimaru, S | 1 |
| Maegawa, H | 1 |
| Ito, H | 1 |
| Marsala, M | 1 |
| Katsube, N | 1 |
| Anand, S | 1 |
| Creager, M | 1 |
| Wilhite, DB | 1 |
| Comerota, AJ | 2 |
| Schmieder, FA | 1 |
| Throm, RC | 1 |
| Gaughan, JP | 1 |
| Rao, AK | 1 |
| Wang, T | 1 |
| Zhong, J | 1 |
| Nakajima, K | 1 |
| Chapman, TM | 1 |
| Goa, KL | 1 |
| Asplund, CA | 1 |
| O'Connor, FG | 1 |
| Samra, SS | 1 |
| Bajaj, P | 1 |
| Vijayaraghavan, KS | 1 |
| Potdar, NP | 1 |
| Vyas, D | 1 |
| Devani, RG | 1 |
| Ballary, C | 1 |
| Desai, A | 1 |
| Hashiguchi, M | 1 |
| Ohno, K | 1 |
| Saito, R | 1 |
| Landi, A | 1 |
| Collinson, DJ | 1 |
| Jacoby, D | 1 |
| Mohler, ER | 3 |
| Collins, P | 1 |
| Brittenden, J | 2 |
| Clagett, GP | 1 |
| Sobel, M | 1 |
| Jackson, MR | 1 |
| Lip, GY | 1 |
| Tangelder, M | 1 |
| Verhaeghe, R | 1 |
| Barnett, AH | 1 |
| Crichton, B | 1 |
| Homer-Vanniasinkam, S | 1 |
| Nakamura, N | 1 |
| Osawa, H | 1 |
| Yamabe, H | 1 |
| Okumura, K | 1 |
| Hamazaki, T | 1 |
| Guest, JF | 1 |
| Davie, AM | 1 |
| Clegg, JP | 1 |
| Gaddi, AV | 1 |
| Cicero, AF | 1 |
| Kim, DH | 1 |
| Finucane, TE | 1 |
| Cassar, K | 1 |
| Bachoo, P | 1 |
| Stewart, KJ | 1 |
| Hobbs, SD | 1 |
| Marshall, T | 1 |
| Fegan, C | 1 |
| Adam, DJ | 1 |
| Stansby, GP | 2 |
| Rowlands, TE | 1 |
| Ishiwata, N | 1 |
| Noguchi, K | 1 |
| Kawanishi, M | 1 |
| Asakura, Y | 1 |
| Hori, M | 1 |
| Mitani, A | 1 |
| Ito, Y | 1 |
| Takahashi, K | 2 |
| Nishiyama, H | 1 |
| Shudo, N | 1 |
| Takahashi, S | 1 |
| Tsuruzoe, N | 1 |
| Nakaike, S | 1 |
| Kumar, M | 1 |
| Lipsitz, EC | 1 |
| Kim, S | 1 |
| Falconer, TM | 1 |
| Eikelboom, JW | 1 |
| Hankey, GJ | 1 |
| Norman, PE | 1 |
| Herd, JA | 3 |
| Isaacsohn, JL | 1 |
| Davidson, M | 2 |
| Cutler, B | 1 |
| Dawson, DL | 5 |
| Cutler, BS | 3 |
| Meissner, MH | 1 |
| Strandness, DE | 3 |
| Crouse, JR | 1 |
| Hunninghake, DB | 1 |
| Gordon, IL | 1 |
| Bortey, EB | 3 |
| Sorkin, EM | 1 |
| Markham, A | 1 |
| Miller, JL | 1 |
| DeMaioribus, CA | 1 |
| Hagino, RT | 1 |
| Light, JT | 1 |
| Bradley, DV | 1 |
| Britt, KE | 1 |
| Charles, BE | 1 |
| Beebe, HG | 3 |
| Ikeda, Y | 1 |
| Bramer, SL | 1 |
| Mallikaarjun, S | 1 |
| Liu, Y | 1 |
| Fong, M | 1 |
| Cone, J | 1 |
| Wang, S | 1 |
| Yoshitake, M | 1 |
| Kambayashi, J | 1 |
| Hobson, RW | 1 |
| Martin, JD | 1 |
| Reilly, MP | 1 |
| Weismantel, D | 1 |
| Tjon, JA | 1 |
| Riemann, LE | 1 |
| Pratt, CM | 1 |
| Lee, TM | 2 |
| Su, SF | 2 |
| Tsai, CH | 1 |
| Lee, YT | 2 |
| Wang, SS | 2 |
| Hwang, JJ | 1 |
| Tseng, CD | 1 |
| Chen, MF | 1 |
| Salles-Cuhna, S | 1 |
| Nehler, MR | 1 |
| Lindmayer, K | 1 |
| Doggrell, SA | 1 |
| Smith, JA | 1 |
| Fernandez, BB | 1 |
| Gamssari, F | 1 |
| Mahmood, H | 1 |
| Ho, JS | 1 |
| Villareal, RP | 1 |
| Liu, B | 1 |
| Rasekh, A | 1 |
| Garcia, E | 1 |
| Massumi, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment[NCT00912756] | Phase 4 | 200 participants (Anticipated) | Interventional | 2009-03-31 | Recruiting | ||
| Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172] | Phase 4 | 164 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)[NCT03883412] | Phase 4 | 60 participants (Anticipated) | Interventional | 2019-02-28 | Recruiting | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study[NCT01291641] | Phase 4 | 342 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Evaluation of the Effect of Cilostazol on the Clinical Outcomes of Rheumatoid Arthritis Patients[NCT05671497] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.065 |
| Cilostazol + Placebo | 0.896 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.001 |
| Cilostazol + Placebo | 0.815 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.241 |
| Cilostazol + Placebo | 0.134 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.267 |
| Cilostazol + Placebo | 0.145 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.166 |
| Cilostazol + Placebo | 0.139 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 13.20 |
| Cilostazol + Placebo | 6.57 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 12.98 |
| Cilostazol + Placebo | 10.01 |
59 reviews available for cilostazol and Intermittent Claudication
| Article | Year |
|---|---|
Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications.
Topics: Animals; Cilostazol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2022 |
Systematic review the efficacy and safety of cilostazol, pentoxifylline, beraprost in the treatment of intermittent claudication: A network meta-analysis.
Topics: Cilostazol; Humans; Intermittent Claudication; Network Meta-Analysis; Pentoxifylline; Randomized Con | 2022 |
How To Assess a Claudication and When To Intervene.
Topics: Angiotensin-Converting Enzyme Inhibitors; Ankle Brachial Index; Cilostazol; Humans; Intermittent Cla | 2019 |
[Prospects of clinical application of cilostazol for peripheral artery disease].
Topics: Cilostazol; Humans; Intermittent Claudication; Peripheral Arterial Disease; Russia; Tetrazoles | 2020 |
Cilostazol: a Review of Basic Mechanisms and Clinical Uses.
Topics: Adenosine; Cilostazol; Humans; Intermittent Claudication; Platelet Aggregation Inhibitors; Stroke; T | 2022 |
Network Meta-Analysis Comparing the Outcomes of Treatments for Intermittent Claudication Tested in Randomized Controlled Trials.
Topics: Cilostazol; Endovascular Procedures; Exercise Therapy; Humans; Intermittent Claudication; Network Me | 2021 |
Cilostazol for intermittent claudication.
Topics: Aged; Bias; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Pento | 2021 |
Endovascular revascularisation versus conservative management for intermittent claudication.
Topics: Cilostazol; Combined Modality Therapy; Conservative Treatment; Exercise Therapy; Humans; Intermitten | 2018 |
[Clinical studies in peripheral arterial occlusive disease: update from the aspects of a meta-narrative review].
Topics: Arterial Occlusive Diseases; Cilostazol; Complementary Therapies; Humans; Intermittent Claudication; | 2013 |
The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication.
Topics: Cilostazol; Clinical Trials as Topic; Drug Approval; Endpoint Determination; Humans; Intermittent Cl | 2014 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int | 2014 |
Cilostazol for intermittent claudication.
Topics: Aged; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Pentoxifyll | 2014 |
Contemporary medical management of peripheral arterial disease: a focus on risk reduction and symptom relief for intermittent claudication.
Topics: Ankle Brachial Index; Cilostazol; Combined Modality Therapy; Exercise Therapy; Humans; Intermittent | 2015 |
Clinical efficacy and safety of cilostazol: a critical review of the literature.
Topics: Animals; Cilostazol; Hemorrhage; Humans; Intermittent Claudication; Peripheral Arterial Disease; Pla | 2015 |
Comparative Effectiveness of Medical Therapy, Supervised Exercise, and Revascularization for Patients With Intermittent Claudication: A Network Meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cilostazol; Comparative Effectiveness Research; Exercise | 2015 |
Safety and efficacy of cilostazol in the management of intermittent claudication.
Topics: Cardiovascular Agents; Cilostazol; Exercise Tolerance; Humans; Intermittent Claudication; Peripheral | 2008 |
Pharmacologic therapy for intermittent claudication.
Topics: Cilostazol; Clinical Trials as Topic; Dietary Supplements; Drugs, Investigational; Exercise Therapy; | 2009 |
[Peripheral arterial disease with lower limb claudication: Medical treatment].
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Cilostazol; Comorbidity; Diabetes Complications; Dr | 2009 |
A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication.
Topics: Cilostazol; Humans; Intermittent Claudication; Predictive Value of Tests; Randomized Controlled Tria | 2010 |
A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.
Topics: Cilostazol; Cost-Benefit Analysis; Humans; Intermittent Claudication; Nafronyl; Nicotinic Acids; Pen | 2011 |
Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.
Topics: Cilostazol; Humans; Intermittent Claudication; Nafronyl; Pain; Pentoxifylline; Peripheral Vascular D | 2012 |
Evidence-based symptom relief of intermittent claudication: efficacy and safety of cilostazol.
Topics: Cilostazol; Clinical Trials as Topic; Exercise; Humans; Intermittent Claudication; Quality of Life; | 2002 |
Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.
Topics: Arteriosclerosis; Cholesterol, HDL; Cilostazol; Clinical Trials as Topic; Humans; Hypolipidemic Agen | 2002 |
Management of patients with intermittent claudication.
Topics: Aspirin; Blood Vessel Prosthesis; Cilostazol; Clopidogrel; Exercise Therapy; Humans; Intermittent Cl | 2002 |
Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.
Topics: Aged; Cilostazol; Exercise Test; Humans; Intermittent Claudication; Intracranial Arterial Diseases; | 2002 |
Can claudication be improved with medication?
Topics: Carnitine; Cilostazol; Humans; Intermittent Claudication; Nafronyl; Pentoxifylline; Platelet Aggrega | 2002 |
Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.
Topics: Aged; Cholesterol, HDL; Cilostazol; Clinical Trials, Phase III as Topic; Double-Blind Method; Exerci | 2002 |
Cilostazol: a review of its use in intermittent claudication.
Topics: Animals; Cilostazol; Clinical Trials as Topic; Humans; Intermittent Claudication; Phosphodiesterase | 2003 |
Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication.
Topics: Alprostadil; Cilostazol; Epoprostenol; Humans; Intermittent Claudication; Platelet Aggregation Inhib | 2004 |
[Secondary prevention and conservative therapy of obliterative arteriosclerosis].
Topics: Arteriosclerosis Obliterans; Cilostazol; Clinical Trials as Topic; Epoprostenol; Exercise; Hematolog | 2004 |
Cilostazol: improving walking distance in patients with intermittent claudication.
Topics: Cilostazol; Exercise Tolerance; Humans; Intermittent Claudication; Phosphodiesterase Inhibitors; Tet | 2004 |
Drug treatment of intermittent claudication.
Topics: Animals; Cilostazol; Clinical Trials as Topic; Humans; Intermittent Claudication; Pentoxifylline; Te | 2004 |
Treatment of intermittent claudication: cilostazol.
Topics: Cilostazol; Clinical Trials as Topic; Humans; Intermittent Claudication; Pentoxifylline; Tetrazoles; | 2004 |
Peripheral arterial disease.
Topics: Angioplasty, Balloon; Cilostazol; Exercise; Humans; Intermittent Claudication; Pentoxifylline; Perip | 2003 |
Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Arterial Occlusive Diseases; Aspirin; Cilostazol; Clopidogrel; Contraindications; Evidence-Based Med | 2004 |
The role of cilostazol in the treatment of intermittent claudication.
Topics: Algorithms; Arteriosclerosis; Cilostazol; Clinical Trials as Topic; Humans; Intermittent Claudicatio | 2004 |
The US experience with cilostazol in treating intermittent claudication.
Topics: Cilostazol; Humans; Incidence; Intermittent Claudication; Platelet Aggregation Inhibitors; Tetrazole | 2005 |
Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination.
Topics: Aspirin; Bleeding Time; Blood Platelets; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; | 2005 |
[Treatment of peripheral obstructive artery disease: a battle that could be winned also with drugs?].
Topics: Arterial Occlusive Diseases; Cilostazol; Drug Therapy, Combination; Europe; Glycosaminoglycans; Huma | 2005 |
Peripheral arterial disease.
Topics: Angioplasty, Balloon; Cilostazol; Coronary Artery Bypass; Exercise; Humans; Hydroxymethylglutaryl-Co | 2006 |
Established and evolving medical therapies for claudication in patients with peripheral arterial disease.
Topics: Ankle; Arterial Occlusive Diseases; Blood Pressure; Brachial Artery; Cilostazol; Exercise Test; Exer | 2006 |
Cilostazol for peripheral arterial disease.
Topics: Aged; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Peripheral | 2007 |
Medical therapy for intermittent claudication.
Topics: Aged; Angiogenic Proteins; Animals; Cardiovascular Agents; Cilostazol; Collateral Circulation; Femal | 2007 |
Cilostazol: a new drug in the treatment intermittent claudication.
Topics: Cilostazol; Humans; Intermittent Claudication; Peripheral Vascular Diseases; Phosphodiesterase 3 Inh | 2007 |
Cilostazol for peripheral arterial disease.
Topics: Aged; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Peripheral | 2008 |
Management of peripheral arterial disease in the elderly: focus on cilostazol.
Topics: Aged; Cilostazol; Diabetic Angiopathies; Dose-Response Relationship, Drug; Dyslipidemias; Humans; Hy | 2008 |
Cilostazol.
Topics: Cilostazol; Humans; Intermittent Claudication; Platelet Aggregation Inhibitors; Randomized Controlle | 1999 |
Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor.
Topics: Animals; Blood Platelets; Cell Division; Cilostazol; Clinical Trials as Topic; Cyclic AMP; Fibrinoly | 1999 |
Cilostazol: treatment of intermittent claudication.
Topics: Cilostazol; Clinical Trials as Topic; Humans; Intermittent Claudication; Phosphodiesterase Inhibitor | 2001 |
Treatment of intermittent claudication with pentoxifylline and cilostazol.
Topics: Aged; Area Under Curve; Cilostazol; Drug Interactions; Exercise Therapy; Humans; Intermittent Claudi | 2001 |
Cilostazol: a novel treatment option in intermittent claudication.
Topics: Cilostazol; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans; Intermittent Claudicat | 2001 |
New treatment options in intermittent claudication: the US experience.
Topics: Arginine; Carnitine; Cilostazol; Endothelial Growth Factors; Exercise Therapy; Humans; Intermittent | 2001 |
Intermittent claudication: effective medical management of a common circulatory problem.
Topics: Angioplasty; Cilostazol; Diagnosis, Differential; Exercise Therapy; Humans; Intermittent Claudicatio | 2001 |
Comparative effects of cilostazol and other therapies for intermittent claudication.
Topics: Cilostazol; Humans; Intermittent Claudication; Pentoxifylline; Platelet Aggregation Inhibitors; Rand | 2001 |
What can I do to continue walking despite intermittent claudication?
Topics: Aspirin; Cilostazol; Clopidogrel; Humans; Intermittent Claudication; Tetrazoles; Ticlopidine; Vasodi | 2001 |
Peripheral arterial disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cilostazol; Diabetes Complications; Diabetes Mellitus; Dis | 2001 |
Current medical therapies for patients with peripheral arterial disease: a critical review.
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Cardiovascular Diseases; Cilostazol; Dia | 2002 |
Pharmacotherapy of intermittent claudication.
Topics: Animals; Anticoagulants; Cardiotonic Agents; Carnitine; Cilostazol; Humans; Intermittent Claudicatio | 2001 |
Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.
Topics: Aged; Cilostazol; Female; Humans; Intermittent Claudication; Male; Middle Aged; Peripheral Vascular | 2002 |
27 trials available for cilostazol and Intermittent Claudication
| Article | Year |
|---|---|
[Randomized study of tolerability, safety and efficacy of Pletax in intermittent claudication].
Topics: Adult; Aged; Cilostazol; Exercise Test; Humans; Intermittent Claudication; Middle Aged; Pentoxifylli | 2021 |
Sustained Effectiveness of Cilostazol After Endovascular Treatment of Femoropopliteal Lesions: Midterm Follow-up From the Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) Study.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Cilostazol; Female; Femoral Ar | 2018 |
Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease.
Topics: Aged; Cilostazol; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Foot Ulcer; Humans; I | 2015 |
Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products.
Topics: Aged; Aged, 80 and over; Ankle Brachial Index; Arterial Occlusive Diseases; C-Reactive Protein; Cilo | 2015 |
The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; alpha-Tocopherol; Ascorbate Oxidase; beta Carotene; C-R | 2009 |
Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication.
Topics: Aged; Angioplasty, Balloon; Cilostazol; Female; Femoral Artery; Graft Occlusion, Vascular; Humans; I | 2009 |
Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Blood Coagulation; Cilostazol; Cross-Over St | 2009 |
A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Chi-Square Distribution; Cilostazol; Dose-Resp | 2012 |
L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Carnitine; Cilostazol; Double-Blind Method; Drug Therapy, Combination; Exercise Test; F | 2012 |
Pharmacological treatment of intermittent claudication does not have a significant effect on gait impairments during claudication pain.
Topics: Aged; Analgesics; Cilostazol; Gait; Gait Disorders, Neurologic; Humans; Intermittent Claudication; M | 2012 |
Cilostazol treatment of claudication in diabetic patients.
Topics: Adult; Cilostazol; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Humans; I | 2002 |
Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Bleeding Time; Cilostazol; Clopidogrel; Drug Therapy, Co | 2003 |
Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication.
Topics: Aged; Cholesterol; Cilostazol; Female; Follow-Up Studies; Humans; Intermittent Claudication; Lipopro | 2003 |
Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication.
Topics: Aged; Cilostazol; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; In | 2003 |
Effects of cilostazol on lipid and fatty acid metabolism.
Topics: Aged; Atherosclerosis; Cilostazol; Double-Blind Method; Fatty Acids; Female; Humans; Intermittent Cl | 2005 |
The effect of supervised exercise and cilostazol on coagulation and fibrinolysis in intermittent claudication: a randomized controlled trial.
Topics: Aged; Antithrombin III; Biomarkers; Cilostazol; Enzyme-Linked Immunosorbent Assay; Exercise Therapy; | 2007 |
Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
Topics: Aged; Cardiovascular Diseases; Cilostazol; Double-Blind Method; Female; Hemorrhage; Humans; Intermit | 2008 |
Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.
Topics: Cilostazol; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Humans; Intermittent Cla | 1998 |
Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.
Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cilostazol; Double-B | 1998 |
Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.
Topics: Adrenergic beta-Antagonists; Aged; Blood Glucose; Cholesterol, HDL; Cilostazol; Cyclic AMP; Diuretic | 1998 |
Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.
Topics: Adrenergic beta-Antagonists; Aged; Blood Glucose; Cholesterol, HDL; Cilostazol; Cyclic AMP; Diuretic | 1998 |
Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.
Topics: Adrenergic beta-Antagonists; Aged; Blood Glucose; Cholesterol, HDL; Cilostazol; Cyclic AMP; Diuretic | 1998 |
Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.
Topics: Adrenergic beta-Antagonists; Aged; Blood Glucose; Cholesterol, HDL; Cilostazol; Cyclic AMP; Diuretic | 1998 |
The effect of withdrawal of drugs treating intermittent claudication.
Topics: Administration, Oral; Adult; Aged; Cilostazol; Cross-Over Studies; Double-Blind Method; Exercise Tes | 1999 |
A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.
Topics: Adult; Aged; Cilostazol; Double-Blind Method; Exercise Test; Female; Humans; Intermittent Claudicati | 1999 |
Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.
Topics: Administration, Oral; Analysis of Variance; Area Under Curve; Cilostazol; Cross-Over Studies; Drug A | 1999 |
A comparison of cilostazol and pentoxifylline for treating intermittent claudication.
Topics: Aged; Cilostazol; Double-Blind Method; Drug Administration Schedule; Exercise Test; Female; Humans; | 2000 |
Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
Topics: Aged; Cilostazol; Diabetic Angiopathies; Double-Blind Method; Endothelial Growth Factors; Exercise T | 2001 |
Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6.
Topics: Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cilostazol; Double-Blind Method; Enzyme Inhib | 2001 |
Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication.
Topics: Aged; Ankle; Blood Pressure; Brachial Artery; Cilostazol; Double-Blind Method; Exercise; Female; Hem | 2001 |
42 other studies available for cilostazol and Intermittent Claudication
| Article | Year |
|---|---|
Cilostazol for Intermittent Claudication Caused by Peripheral Artery Disease.
Topics: Cilostazol; Humans; Intermittent Claudication; Peripheral Arterial Disease; Tetrazoles; Vasodilator | 2022 |
Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease.
Topics: Aged; Cilostazol; Female; Humans; Intermittent Claudication; Male; Middle Aged; Pain; Peripheral Art | 2022 |
Real-World Safety and Effectiveness of Controlled-Release Cilostazol in Patients with Symptomatic Peripheral Artery Disease.
Topics: Cilostazol; Coronary Artery Disease; Delayed-Action Preparations; Drug-Related Side Effects and Adve | 2023 |
[Clinical study of efficacy and safety of Aducil in patients with chronic lower limb ischaemia].
Topics: Cilostazol; Humans; Intermittent Claudication; Ischemia; Lower Extremity; Platelet Aggregation Inhib | 2019 |
New treatments for peripheral artery disease.
Topics: Ankle Brachial Index; Anticholesteremic Agents; Cilostazol; Diet, Healthy; Dual Anti-Platelet Therap | 2020 |
Cilostazol and peripheral artery disease-specific health status in ambulatory patients with symptomatic PAD.
Topics: Aged; Cilostazol; Female; Health Status; Humans; Intermittent Claudication; Male; Middle Aged; Perip | 2020 |
Cilostazol improves the quality of life and lower-limb functional capacity also in diabetic patients
Topics: Aged; Case-Control Studies; Cilostazol; Diabetes Complications; Diabetes Mellitus; Female; Humans; I | 2020 |
Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany.
Topics: Aged; Cardiovascular Diseases; Cilostazol; Databases, Factual; Dose-Response Relationship, Drug; Dru | 2018 |
Cilostazol promotes mitochondrial biogenesis in human umbilical vein endothelial cells through activating the expression of PGC-1α.
Topics: Base Sequence; Cilostazol; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein | 2013 |
Effect of cilostazol prescribed in a pragmatic treatment program for intermittent claudication.
Topics: Aged; Cilostazol; Exercise; Female; Humans; Intermittent Claudication; Male; Medication Adherence; M | 2014 |
Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Arginine; Cilostazol; Diet, High-F | 2014 |
Cilostazol and outcome in outpatients with peripheral artery disease.
Topics: Aged; Cilostazol; Female; Fibrinolytic Agents; Hemorrhage; Humans; Intermittent Claudication; Male; | 2014 |
Acute myocardial infarction after cilostazol use in a patient with systemic lupus erythematosus.
Topics: Aged; Cilostazol; Creatine Kinase, MB Form; Electrocardiography; Female; Humans; Intermittent Claudi | 2015 |
Cilostazol blocks pregnancy in naturally cycling swine: An animal model.
Topics: Animals; Cilostazol; Contraceptive Agents, Female; Estrus; Female; Humans; Intermittent Claudication | 2015 |
Patterns and determinants of use of pharmacological therapies for intermittent claudication in PAD outpatients: results of the IDOMENEO study.
Topics: Aged; Ankle Brachial Index; Cilostazol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito | 2017 |
[Cilostazol is effective and safe option for the treatment of intermittent claudication. Results of the NOCLAUD study].
Topics: Cilostazol; Exercise Test; Female; Humans; Hungary; Intermittent Claudication; Male; Platelet Aggreg | 2017 |
Improving Lower Extremity Functioning in Peripheral Artery Disease: Exercise, Endovascular Revascularization, or Both?
Topics: Adult; Cilostazol; Combined Modality Therapy; Endovascular Procedures; Exercise Test; Exercise Thera | 2017 |
Peripheral artery disease: current insight into the disease and its diagnosis and management.
Topics: Ankle Brachial Index; Cardiovascular Diseases; Cilostazol; Diagnosis, Differential; Disease Progress | 2010 |
Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes.
Topics: Aged; Analysis of Variance; Biomechanical Phenomena; Cilostazol; Female; Gait; Humans; Imaging, Thre | 2010 |
Treatment of superficial and profunda femoral artery bifurcation lesions: still a procedure only for surgeons?
Topics: Aged; Atherosclerosis; Catheters; Chronic Disease; Cilostazol; Coronary Artery Bypass; Coronary Arte | 2012 |
Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease.
Topics: Cilostazol; Cost-Benefit Analysis; Decision Support Techniques; Humans; Intermittent Claudication; M | 2014 |
The role of cilostazol (Pletal) in the management of intermittent claudication.
Topics: Aged; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Phosphodiesterase Inhibitors; Plat | 2003 |
Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol.
Topics: Alprostadil; Animals; Body Weight; Cilostazol; Disease Models, Animal; Exercise Test; Intermittent C | 2003 |
[Peripheral arterial occlusive disease (PAVK)].
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Arteries; Cilostazol; Evidence-Based Medicine; Ex | 2003 |
Drugs for intermittent claudication.
Topics: Cilostazol; Diabetes Complications; Exercise Therapy; Female; Ginkgo biloba; Humans; Hyperlipidemias | 2004 |
An unusual cause of exertional leg pain.
Topics: Adult; Anticoagulants; Antihypertensive Agents; Cilostazol; Drug Therapy, Combination; Femoral Arter | 2004 |
Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK.
Topics: Adult; Cilostazol; Cost-Benefit Analysis; Humans; Intermittent Claudication; Nafronyl; Pentoxifyllin | 2005 |
Exercise and peripheral arterial disease.
Topics: Cilostazol; Exercise Therapy; Humans; Intermittent Claudication; Pentoxifylline; Peripheral Vascular | 2006 |
Medical management of peripheral arterial disease.
Topics: Cilostazol; Humans; Intermittent Claudication; Peripheral Vascular Diseases; Tetrazoles; Vasodilator | 2006 |
NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model.
Topics: Animals; Body Temperature; Cilostazol; Hindlimb; Humans; Intermittent Claudication; Male; Phosphodie | 2007 |
Antithrombotic therapy in peripheral arterial disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathie | 2008 |
Cilostazol approved for use in intermittent claudication.
Topics: Cilostazol; Drug Approval; Humans; Intermittent Claudication; Phosphodiesterase Inhibitors; Platelet | 1999 |
Cilostazol for intermittent claudication.
Topics: Cilostazol; Diltiazem; Drug Interactions; Erythromycin; Humans; Intermittent Claudication; Phosphodi | 1999 |
Intermittent claudication revisited: the value of medical therapy.
Topics: Cilostazol; Cost-Benefit Analysis; Exercise Test; Exercise Therapy; Humans; Intermittent Claudicatio | 1999 |
Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication.
Topics: Adenosine; Animals; Blood Pressure; Cilostazol; Dose-Response Relationship, Drug; Heart Rate; Humans | 2000 |
Is cilostazol more effective than pentoxifylline in the treatment of symptoms of intermittent claudication?
Topics: Cilostazol; Evidence-Based Medicine; Humans; Intermittent Claudication; Pentoxifylline; Tetrazoles; | 2001 |
A new treatment for peripheral arterial disease.
Topics: Cilostazol; Humans; Intermittent Claudication; Pentoxifylline; Peripheral Vascular Diseases; Platele | 2001 |
Analysis of the cilostazol safety database.
Topics: Adverse Drug Reaction Reporting Systems; Cilostazol; Humans; Intermittent Claudication; Pentoxifylli | 2001 |
Cilostazol in intermittent claudication.
Topics: Cilostazol; Humans; Intermittent Claudication; Pentoxifylline; Phosphodiesterase Inhibitors; Quality | 2002 |
Cilostazol.
Topics: Animals; Bronchodilator Agents; Cardiovascular System; Cilostazol; Clinical Trials as Topic; Drug In | 2002 |
A rational approach to diagnosis and treatment of intermittent claudication.
Topics: Algorithms; Blood Pressure Determination; Cilostazol; Disease Progression; Exercise Test; Hematologi | 2002 |
Rapid ventricular tachycardias associated with cilostazol use.
Topics: Aged; Aged, 80 and over; Cilostazol; Female; Humans; Intermittent Claudication; Phosphodiesterase In | 2002 |